Prothena Corporation plc
NASDAQ:PRTABiotechnology
+$0.33 today
- Market cap
- $428.77M
- Beta
- -0.32
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.81
Volume 0.76M
Average 0.51M
PRTA Total Liabilities
Everything the company owes to creditors and other parties.
Prothena Corporation plcNASDAQ: PRTA
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 35.3% from a year ago
Total liabilities stood at $37.28M at the end of Q1 FY2026, down 35.3% from a year earlier and down 19.5% from the prior quarter. Over 3 fiscal years it compounded at -30.2% a year.
Context
- Total liabilities amounted to 10.7% of total assets at the end of Q1 FY2026, down 1.0 pp from a year earlier.
- Total liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -35.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 46.33M USD
- Year-over-year change
- -23.0%
- 4-year CAGR
- -24.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.33M | -23.0% |
| FY2024 | 2024-12-31 | 60.18M | -55.4% |
| FY2023 | 2023-12-31 | 135.02M | -0.7% |
| FY2022 | 2022-12-31 | 135.99M | -5.1% |
| FY2021 | 2021-12-31 | 143.32M | — |
Total Liabilities vs competitors
How PRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -35.3% is the 8th highest of 10, against a peer median of -5.7%.
- Total liabilities amounts to 10.7% of total assets for PRTA, versus a peer median of 27.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $13.24B USD | +23.8% | +0.1% | 41.3% | |
| Jun 2026 | $322.78M USD | +131.9% | -32.0% | 27.9% | |
| Mar 2026 | CHF 105.89M CHF | -8.9% | +86.2% | 77.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $83.2M USD | +193.1% | -53.6% | 54.1% |
| Mar 2026 | $58.36M USD | -1.5% | +6.9% | 22.2% | |
| Mar 2026 | $46.15M USD | -5.7% | +88.6% | 34.5% | |
| Mar 2026 | $37.28M USD | -35.3% | -30.2% | 10.7% | |
| Jun 2026 | $7.29M USD | -26.3% | -11.5% | 12.9% | |
| Dec 2025 | $6.37M USD | -51.5% | -4.3% | 4.8% | |
| Mar 2026 | $6.23M USD | -44.5% | +11.5% | 17.2% | |
| Peer median (excluding PRTA) | — | -5.7% | +0.1% | 27.9% | |
Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 579.09M | 710.41M | 618.83M | 471.39M | 307.53M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 13K | 62K | 5.16M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 766K | 1.71M | 3.49M | 1.17M | 1.75M |
| Total Current Assets | 584.81M | 719.1M | 639.28M | 485.41M | 315.19M |
| Property, Plant & Equipment (Net) | 14.14M | 8.01M | 16M | 13.79M | 10.27M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 860K | 860K |
| Tax Assets | 7.07M | 18.2M | 33.89M | 43.24M | 0 |
| Other Non-current Assets | 3.35M | 12.73M | 7.21M | 3.81M | 482K |
| Total Non-current Assets | 24.56M | 38.94M | 57.1M | 61.7M | 11.61M |
| Total Assets | 609.37M | 758.04M | 696.38M | 547.11M | 326.8M |
| Account Payables | 3.69M | 9.27M | 25.39M | 7.77M | 5.88M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.89M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.66M | 11.44M | 0 | 8.85M | 2.66M |
| Other Current Liabilities | 405K | 503K | 2.13M | 1.38M | 29.42M |
| Total Current Liabilities | 33.45M | 50.15M | 56.89M | 48.5M | 40.84M |
| Long-term Debt | 0 | 0 | 0 | 0 | 5.49M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 102.93M | 85.29M | 67.41M | 3.45M | 0 |
| Other Non-current Liabilities | 553K | 553K | 0 | 0 | (5.49M) |
| Total Non-current Liabilities | 109.87M | 85.85M | 78.13M | 11.68M | 5.49M |
| Total Liabilities | 143.32M | 135.99M | 135.02M | 60.18M | 46.33M |
| Common Stock | 466K | 521K | 537K | 538K | 538K |
| Retained Earnings | (716.05M) | (833M) | (980.03M) | (1.1B) | (1.35B) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 466.04M | 622.04M | 561.37M | 486.93M | 280.47M |
| Total Debt | 12.33M | 6.47M | 11.84M | 10.84M | 13.86M |
| Net Debt | (566.77M) | (703.93M) | (607M) | (460.55M) | (293.67M) |
Prothena Corporation plc
NASDAQ:PRTA
Intrinsic Alpha fair value
Locked
Current Price
$8.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.